Somewhere tonight, a person who is genuinely struggling is going to open Reddit, type a question about getting a prescription, and find a step-by-step answer written by a stranger. It will tell them what to say, what not to say, and which kinds of clinicians to avoid. In a few weeks, some version of that person will be sitting across from you.
That is the uncomfortable starting point of a clinical update in the June/July 2026 issue of The Carlat Psychiatry Report, written by Garrett Rossi, MD, an inpatient and consult attending psychiatrist at AtlantiCare Regional Medical Center in New Jersey. The piece is called “Street Smarts in Psychopharm: What Every Clinician Needs to Know,” and it is the kind of article nobody puts on a board exam blueprint but every working prescriber needs. If you are training to become a PMHNP, I would argue it matters more than a lot of what is on the blueprint.
What Dr. Rossi Is Actually Describing
According to Rossi, forums on Reddit and TikTok, along with assorted message boards, now circulate detailed advice on how to obtain Adderall, Xanax, and Ambien. The advice includes exaggerating or inventing symptoms, working telehealth platforms that move fast, and steering clear of cautious prescribers. He ties some of this to the telehealth expansion that came with COVID-19, noting that certain platforms put convenience and profit ahead of clinical rigor, a point he supports by citing Reeves and Ayers in the Journal of Medical Internet Research in 2021.
Here is the part I want you to hold onto, because it is the part that separates a good clinician from a cynical one. Rossi is explicit that some of the people following these scripts are not schemers. Some are desperate. They are trying to get relief inside a fragmented healthcare system where a real appointment can take months, and the internet gave them a map. If you walk into every visit assuming bad intent, you will insult people who are suffering, and you will miss the ones who need you most.
If you walk in naive, though, you become the prescriber the forums are warning each other about as an easy target. Rossi’s whole argument lives in the space between those two failures.
The Scripts, Drug by Drug
Rossi lays out what the online playbooks tend to look like, and reading it feels a bit like seeing the other team’s game film.
For benzodiazepines, the pattern he describes is that patients avoid naming the drug. They describe vague anxiety or panic, say that SSRIs and therapy already failed, and stress that things are urgent. Some, he writes, move from clinic to clinic until they land with a prescriber who does not dig deep.
For ADHD, the picture is a little different, and a little more complicated, because the diagnosis itself has become a cultural conversation. Rossi points to the spread of self-diagnosis built on broad, everyday complaints such as trouble multitasking or losing focus, which blurs the line between ordinary life difficulty and a disorder. He cites Schiros and colleagues in European Child and Adolescent Psychiatry, published online in June 2025, on that point. The advice circulating online, he reports, includes reciting DSM-5 criteria word for word, claiming a prior diagnosis, asking for an assessment, and mentioning a failed trial of atomoxetine. He also describes a viral post that linked an ADHD checklist to a telehealth ad promising a 15-minute screening and same-day prescribing.
Pause on that last detail for a second. A fifteen-minute screening with a same-day prescription is not an evaluation. It is a transaction. And you will be trained, paid, and licensed to do something better.

Why This Belongs in Your Training, Not Just Your Inbox
I want to be honest about something. Most of us in this field absorb the idea that good prescribing is mostly about knowing mechanisms, doses, and interactions. Those matter, and you will be tested on them. But the moment you hold a prescriber’s license, a second skill starts to matter just as much: deciding what to do when the story in front of you is incomplete, or rehearsed, or both.
Your graduate program probably gives you a lecture on controlled substances and a unit on substance use disorders. It is much less likely to give you a script for the moment a patient says “I think I have ADHD, and I’ve tried everything else” and you have 30 minutes, a waiting room full of people, and a pharmacy that will fill whatever you send.
That is the gap Rossi is filling. His answer is not suspicion. His closing line, as the article frames it, is that the best defense is “structure, curiosity, and firm but compassionate boundaries” rather than cynicism. I have thought about that phrase more than I expected to. Structure, curiosity, boundaries. You can practice all three before you ever see a real patient.
The Toolkit He Recommends
Here is where the article gets practical, and where I think PMHNP students can start building habits now.
Use structured assessment, not a vibe. For ADHD, Rossi points to the DIVA-5, the CAARS, the ASRS, and the Brown Attention Scales, and he notes the DIVA-5 can be had for a one-time fee of about twelve dollars. He then adds the piece many clinicians skip: pair the tools with collateral history, academic or work records, and documentation of earlier treatment. He cites Ramos-Quiroga and colleagues in the Journal of Attention Disorders in 2019 for this approach. A rating scale tells you what a patient endorsed. Collateral tells you whether the story holds together over time.
Get the substance and prescribing history. Ask about current and past stimulants, benzodiazepines, and opioids, and check the state prescription drug monitoring program (PDMP) before you start any controlled substance. This is a routine step, not an accusation. Say it that way out loud: “I check this for everyone.”
Ask for the people who know the patient. Relatives, teachers, report cards. Childhood evidence matters a great deal when the question is whether symptoms were present before adulthood.
Write the treatment agreement. Rossi recommends spelling out refill policies, what happens with lost prescriptions, and functional goals that go beyond symptom relief. A patient who wants to be well will usually welcome a clear plan. A patient who is looking for a supply often will not.
Reach for safer options first when the picture is murky. For ambiguous ADHD presentations, he suggests non-stimulants such as bupropion, atomoxetine, or guanfacine. For anxiety, especially a first presentation, he points toward SSRIs or SNRIs, buspirone, hydroxyzine, or therapy ahead of benzodiazepines. That is also, not by coincidence, close to how many exam questions are built.
Follow up monthly. Check symptom control, function, and adherence. Early follow-up is how you catch misuse while it is still a conversation rather than a crisis.

Saying No Without Burning the Bridge
This is the skill I wish someone had drilled into me earlier. Rossi encourages clinicians to frame a decline around safety and clinical appropriateness, rather than confrontation. Think about the difference between these two sentences.
“I don’t think you really have ADHD.”
“I’m not comfortable starting a stimulant until I’ve seen your school records and spoken with someone who knew you as a kid, because I want to make sure it’s the right medicine for you.”
The first one ends the relationship. The second one keeps the door open, gives the patient something to do, and protects you. It also happens to be true. Nothing about it requires you to judge anyone’s character. You are describing your standard of care, and your standard of care applies to everyone.
A patient who is truly struggling will usually hear that sentence as someone finally taking them seriously. A patient who was only after a prescription will usually go elsewhere. Both outcomes are fine. Neither required you to lose your composure.
What This Means for the Boards
I will not pretend this specific article is going to show up on a certification exam. It will not. But look at what it reinforces.
Exam writers love first-line treatment logic: the first-time anxiety patient should not start on a benzodiazepine; the ADHD patient with a substance use history is a reason to think about non-stimulants. They love safety monitoring, which includes the PDMP and follow-up intervals. They love the difference between a screening tool and a diagnostic evaluation. They love scenarios where the safest answer is the one that gathers more information before prescribing.
If you train yourself to think the way Rossi describes, you will find that many of the “best next step” questions get easier, because you are already asking the question underneath the question: what do I still need to know before I write this?
A Quick Word About Compassion
I do not want you to finish this post feeling suspicious of your future patients. That is the wrong takeaway, and I do not think it is what Rossi intends either.
The honest truth is that a lot of people reach for internet scripts because the front door is closed. They could not get an appointment. They could not afford one. They were dismissed the last time they said “I can’t focus” or “I can’t sleep.” When a system fails people, they improvise, and some of them improvise with advice from strangers.
Your job is to be the clinician who is hard to game and easy to trust. Those two things are not opposites. A well-organized evaluation is actually a form of respect. It tells the patient: your problem is real enough that I am going to do this properly.
Three Things to Do This Week
You do not need a license to start building this skill. Here is what I would try.
First, look up the ASRS and the DIVA-5 and read through them. Notice how many questions ask about childhood, not just the present. Second, find out how your state’s PDMP works and what a clinician is expected to do with it before prescribing. Third, practice saying a clear, kind “not yet” out loud, to a classmate, a mirror, or the dog. It will feel awkward the first ten times. By the fiftieth it will sound like you.
And if you have access to The Carlat Psychiatry Report through your program or a preceptor, read the Rossi piece in full. I have summarized it here, but the summary table at the end, which pairs each online tactic with a matching clinical response, is worth studying on its own.
You Are Going to Be Good at This
Here is what I believe about the people reading this blog. You are putting yourselves through a demanding program because you want to help people with some of the hardest problems in medicine. That instinct is the most important thing you bring. It just needs a structure to live inside.
Structure, curiosity, and firm but compassionate boundaries. Learn those, and the internet’s playbooks will stop being a threat and start being a reminder of why good training exists.
Ready to turn that training into a passing score and a confident start to practice? Head over to pmhnpreview.org for more board prep, career guidance, and the mindset support to carry you all the way through.
Source: Garrett Rossi, MD, “Street Smarts in Psychopharm: What Every Clinician Needs to Know,” The Carlat Psychiatry Report, June/July 2026 (General Psychiatry, Clinical Update). This post is educational and is not a substitute for clinical supervision or your program’s guidance.
